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Summary 
The karyophilic properties of the viral matrix (MA) pro- 
tein govern HIV nuclear import in nondividing cells 
such as macrophages. A critical regulator of this pro- 
cess is the C-terminal tyrosine phosphorylation of MA 
during virus maturation. Here, we reveal the mecha- 
nism of this phenomenon, by demonstrating that tyro- 
sine phosphorylation induces the binding of MA to in- 
tegrase (IN). This leads to the incorporation of MA 
molecules into virus cores, and subsequently into un- 
coated viral nucleoprotein complexes. A direct inter- 
action between tyrosine-phosphorylated MA and the 
central domain of IN can be demonstrated in vitro. It 
is blocked by phosphotyrosine, indicating that IN rec- 
ognizes the phosphorylated C-terminal residue of MA. 
These results explain how the karyophilic potential of 
MA is conferred to the HIV nucleoprotein complex. 
Introduction 
Human immunodeficiencyvirus(HIV) replication in nonmi- 
totic cells such as terminally differentiated macrophages 
is likely crucial for its transmission and for its spread and 
persistence in the body, as well as for AIDS induction (Mel- 
tzer and Gendelman, 1992). In contrast with oncoretrovi- 
ruses (Humphries and Temin, 1972, 1974; Roe et al., 
1993; Lewis and Emerman, 1994) HIV can infect nonpro- 
liferating targets, because it encodes determinants that 
govern the active transport of the virus nucleoprotein com- 
plex through the nucleopore, allowing integration into the 
host cell chromosome in the absence of mitosis (Weinberg 
et al., 1991; Bukrinsky et al., 1992; Lewis et al., 1992). 
Two viral proteins, the viral matrix protein (MA) and Vpr, 
mediate this process (Bukrinsky et al., 1993; Heinzinger 
et al., 1994; von Schwedler et al., 1994). MA, the myristoy- 
lated N-terminal cleavage product of the HIV-1 ~55 Gag 
precursor, has intrinsic karyophilic properties conferred 
by a conserved stretch of basic residues, which acts as 
a nuclear localization signal (NLS) (Bukrinsky et al., 1993). 
In the absence of a functional vpr gene, MA-NLS mutant 
viruses fail to replicate efficiently in macrophages, owing 
to a block in nuclear import (Bukrinsky et al., 1993; Hein- 
zinger et al., 1994; von Schwedler et al., 1994). As pre- 
dicted from this result, MA can be detected in the nucleus 
of newly infected cells during the early steps of the replica- 
tive cycle (Sharova and Bukrinskaya, 1991). In contrast, 
in virus-producing cells, MA localizes to the plasma mem- 
brane, owing to the combined effectsof myristoylation and 
of positively charged residues near the protein N-terminus 
(Yuan et al., 1993; Spearman et al., 1994; Zhou et al., 
1994). These latter residues are thought to establish elec- 
trostatic interactions with the negatively charged phospho- 
lipids on the inner leaflet of the lipid bilayer (Zhou et al., 
1994). The membrane association of MA is essential for 
both the proper assembly of virions and their efficient re- 
lease from cells (Varmus and Swanstrom, 1984). 
The myristoylation signal and the NLS thus exert con- 
flicting influences on the subcellular localization of MA. 
We recently demonstrated that a key to the sequential 
action of these motifs is the phosphorylation of a portion 
of MA molecules on the C-terminal tyrosine at the time of 
virus maturation, by a virion-associated cellular tyrosine 
kinase (Gallay et al., 1995). After viral entry, tyrosine- 
phosphorylated MA molecules are preferentially trans- 
ported to the nucleus, whereas the bulk of MA, not phos- 
phorylated on tyrosine, stays at the plasma membrane. 
Replacing the C-terminal tyrosine of MA by a phenylala- 
nine does not impair HIV-1 replication in dividing cells, 
but the resulting virus is markedly defective for growth in 
terminally differentiated macrophages, owing to a block 
in nuclear import. 
MA tyrosine phosphorylation does not increase the kary- 
ophilic potential of MA per se, because nonmyristoylated 
MA is effectively translocated to the nucleus even though 
it is not tyrosine phosphorylated (Gallay et al., 1995). It is 
therefore more likelythat tyrosine phosphorylation triggers 
the redistribution of MA from the membrane toward the 
inner regions of the virus, thereby allowing the NLS to play 
its role during the early steps of infection. This could be 
achieved by disrupting electrostatic interactions between 
MA and the membrane, analogous to what is thought to 
account for the phosphorylation-induced cytosolic release 
of MAHCKS and pp60”-” (Thelen et al., 1991; Walker et 
al., 1993). Alternatively, albeit not exclusively, phosphory- 
lation could stimulate the binding of MA to another compo- 
nent of the viral nucleoprotein core. Here, we present evi- 
dences supporting this second mechanism. 
Results 
Tyrosine-Phosphorylated MA Is Found 
in the Virion Core 
The subviral distribution of tyrosine-phosphorylated MA 
was examined by partial lysis of virions followed by su- 
crose gradient fractionation, which separates viral cores 
and membranes. HIV-2 was used for this experiment, be- 
cause HIV-1 particles were found to be too unstable in the 
presence of detergent. Fractions were analyzed for their 
content of reverse transcriptase (FIT), p27 capsid (CA), 
integrase (IN), envelope (Env), MA, and tyrosine-phos- 
phorylated MA through a combination of enzymatic and 
immunological assays (Figure 1A). Intact HIV-2 virions ex- 
hibited a density of 1.15 to 1.19 g/cm3, as indicated by 
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Figure 1. Phosphotyrosine-Dependent Incorporation of MA into the 
Virion Core 
(A) Purified HIV-2 virions were fractionated on a sucrose gradient, 
before (top) and after (bottom) partial lysis. Fractions were evaluated 
for their content in RT activity (by an exogenous RT assay) and p27 
CA antigen (using the HIV-1 ~24 ELISA), as well as for the presence 
of IN, MA, tyrosine-phosphorylated MA, and Env (by Western blot). 
The p24 ELISA is approximately 1000-5000 times less sensitive for 
the HIV-2 CA than for its HIV-I counterpart, so that the numbers shown 
here only represent relative values. 
(B) Cytoplasmic extracts and virions released from CEM cells infected 
with wild-type or tyrosine-mutated HIV-2, as well as purified viral cores, 
were analyzed by Western blot with the indicated antibodies, with 
(pTyr, CA, Env) or without (MA) prior immunoprecipitation. 
the recovery of all viral proteins in the corresponding frac- 
tions of the gradient (Figure 1 A, top). After the particles 
had been treated with a mild detergent, a sharp peak of 
RT activity was detected at a density of 1.24-l .25 g/cm3 
(Figure 1 A, bottom). This peak also contained CA and IN, 
but no Env, indicating that it likely corresponded to viral 
cores. Most MA molecules were retained at the top of the 
gradient, together with Env, consistent with the membrane 
association of these two proteins. In contrast, all 
tyrosine-phosphorylated MA molecules were detected in 
the fractions corresponding to viral cores. 
A mutant HIV-2 clone was generated, in which the C-ter- 
minal tyrosine of MAwas replaced by a phenylalanine. The 
resulting virus, named MAY,~~FHIV-~~,X,, grew with normal 
kinetics in proliferating T cells (data not shown). Cyto- 
plasmic extracts and virions released from CEM cells in- 
fected with wild-type or tyrosine-mutated HIV-2 were com- 
pared for their content in total and tyrosine-phosphorylated 
MA(Figure 1 B, lanes l-4). The MAY135Fmutation abolished 
the reactivity of MA with a phosphotyrosine-specific anti- 
body, indicating that HIV-2 MA, like its HIV-1 counterpart, 
undergoes phosphorylation on its C-terminal tyrosine. Vi- 
ral cores prepared from wild-type and mutant HIV-2 were 
then examined (Figure 1 B, lanes 5 and 6). Whereas the 
mutation did not affect the subviral distribution of CA and 
Env, MA levels in cores of MAY135FHlV-2ROD were greatly 
reduced compared with those in the wild-type control. 
Tyrosine-Phosphorylated MA Is Associated 
with the HIV-1 Nucleoprotein Complex 
A prediction derived from this and our previous experi- 
ments was that tyrosine-phosphorylated MA molecules 
might be selectively incorporated into uncoated viral nu- 
cleoprotein complexes, following fusion of the virus and 
target cell membranes. To address this point, cytoplasmic 
extractsof Tcells freshly infected with HIV-1 were fraction- 
ated on a sucrose gradient. Fractions were analyzed for 
their content in viral proteins and DNA by Western blot 
and polymerase chain reaction (PCR), respectively(Figure 
2). The p24 CA antigen as well as the bulk of MA were 
detected in the region of the gradient with the lowest den- 
sity, indicating that these proteins were dissociated from 
the viral nucleoprotein complex. In contrast, a peak of RT 
activity was detected at a density of 1.21-l .25 g/cm3, to- 
gether with high levels of IN, Vpr, and nucleocapsid (NC), 
and the viral DNA. These fractions, consistent with par- 
tially purified viral nucleoprotein complexes, also con- 
tained all tyrosine-phosphorylated MA molecules, even 
though this subspecies only represented a small fraction 
of the total amount of MA. 
To examine further the subcellular distribution of vari- 
ous proteins during the early steps of the virus life cycle, 
cells were acutely infected with either wild-type HIV-1 or 
mutant MAY,,2F, in which the C-terminal tyrosine of MA is 
changed to phenylalanine (Gallay et al., 1995). At 1 hr and 
8 hr postinfection, cells were fractionated into membranes, 
cytosol, and nucleus. Fractionswereanalyzed by immuno- 
precipitation and Western blot with antibodies against MA, 
phosphotyrosine, IN, Vpr, NC, and Env, as well as by mea- 
suring RT activity and p24 antigen content (Figure 3). At 
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Figure 2. Tyrosine-Phosphorylated MA Associates with the Virus Nu- 
cleoprotein Complex 
Cytoplasmic extracts of SupTl cells acutely infected with HIV-1 were 
fractionated on a sucrose gradient, and fractions were evaluated first 
for the presence of various viral proteins by a combination of immuno- 
precipitations and Western blots (for Vpr a simple Western blot was 
used) and second for their content in viral DNA by PCR. 
1 hr postinfection, in cells infected with either virus, Env 
was found in membranes (lane l), whereas IN, Vpr, NC, 
~24, and RT were detected in the cytosol (lane 2; data 
not shown). In wild-type infected cells, although MA was 
associated predominantly with membranes (lane l), some 
of this protein, and most importantly all of its tyrosine- 
phosphorylated component, was present in the cytosol 
(lane 2). In contrast, in MAyIspF-infected cells, no MA was 
detected in the cytosol (lane 2). At 8 hr postinfection, in 
cells infected with either virus, approximately half of IN, 
Vpr, NC, and RT had migrated to the nucleus (lane 6), 
whereas CA remained in the cytosol (lane 5). Although 
tyrosine-phosphorylated MA was found exclusively in the 
nucleus of wild-type infected cells (lane 6), MA was re- 
stricted to the membrane fraction of cells inoculated with 
the MAWZ variant (lane 4). These data thus confirm that 
the C-terminal tyrosine of MA is necessary for its nuclear 
migration. 
Tyrosine-Phosphorylated MA Is Associated 
with lntegrase In Vivo 
The possible association of tyrosine-phosphorylated MA 
with otherviral proteins was examined by coimmunopreci- 
pitation (Figure 4). In partially purified viral nucleoprotein 
complexes, MA- and phosphotyrosine-specific antibodies 
could immunoprecipitate IN (Figure 4A), but failed to pre- 
cipitate either NC, Vpr, or RT (data not shown). Recipro- 
cally, immunoprecipitations with IN-specific antibodies se- 
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Figure 3. Subcellular Localization of Viral Proteins during the Early 
Steps of Infection 
Extracts of P4-2 cells acutely infected with wild-type HIV-I, or with 
the tyrosine-mutated MAY132F variant, were fractionated at 1 and 8 hr 
postinfection in membranes, cytosol, and nucleus. The presence of 
various viral proteins was monitored by immunoprecipitation followed 
by Western blot with the indicated antibodies (top: for Vpr, a simple 
Western blot was used), or by measuring RT activity and p24 CA 
antigen content (bottom graph). The subcellular distributions of NC, 
Vpr, Env, ~24, and FIT in MAv,&nfected cells were identical to those 
observed for wild type (data not shown). 
lectively depleted MA from viral nucleoprotein complexes 
(data not shown). In contrast, in cells infected with the 
MAY132F virus, no association between IN and MA was de- 
tected (data not shown), corroborating the distinct subcel- 
lular localizations of these two proteins (see Figure 3). 
IN- and phosphotyrosine-specific antibodies could also 
immunoprecipitate all MA molecules contained in purified 
HIV-2 cores (Figure 4B), but not RT or p27 CA (data not 
shown). This indicates that the association between MA 
and IN, already established in virions, does not require 
structural modifications occurring after viral entry, nor cel- 
lular factors that might act on the virus during uncoating. 
These results raised the possibility that MA transloca- 
tion in target cells might need the binding of this protein to 
integrase. To test this hypothesis, an HIV-1 mutant lacking 
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Figure 4. MA Assocrates with the HIV Nucleoprotein Complex through 
an Interaction with lntegrase 
(A) HIV-1 nucleoprotein complexes partially purified from the cyto- 
plasm of acutely infected SupTl cells were immunoprecipitated with 
the antibodies shown on topof each lane. Bound material and superna- 
tant were analyzed by Western blot with indicated antiserums. 
(B) Same experiment, on purified HIV-2 cores. RT activity and p27 
CA antigen were not coimmunoprecipitated by the various antibodies 
(data not shown). 
(C) MA subcellular localization in cells infected with IN-defective HIV-l, 
analyzed as described in Figure 3. 
integrase, called AIN, was generated by introducing a stop 
codon at the 3’end of the RTcoding sequence. This modifi- 
cation had no effect on the production of viral particles 
(data not shown). Furthermore, the translocation of NC 
and Vpr was as efficient in AIN- as in wild type-infected 
cells (compare Figure 4C with Figure 3). In contrast, MA 
was retained at the membrane of cells inoculated with 
the integrase-defective virus. The presence of IN is thus 
required for the cytosolic and nuclear translocation of MA 
during the early steps of HIV infection. 
Phosphotyrosine-Mediated Binding of MA to the Core 
Domain of lntegrase In Vitro 
The data presented so far would not allow one to conclude 
that MA and integrase interact directly. This question was 
addressed in vitro by using Escherichia coli-produced re- 
combinant molecules (Figure 5). Two forms of HIV-1 MA 
were tested: the wild-type protein and the MAYIsZF mutant. 
The effect of tyrosine phosphorylation on MA-IN binding 
was further assessed by treating the two MA variants with 
Src kinase. In vitro, Src specifically phosphorylates the 
C-terminal tyrosine of MA, as demonstrated by phosphoa- 
mino acid analysis and tryptic peptide mapping of Src- 
phosphorylated wild-type MA, as well as by the failure of 
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Figure 5. Phosphotyrosine-Dependent Binding of MA to lntegrase In 
Vitro 
(A) Recombinant wild-type or tyrosine-mutated MA proteins were 
mixed with integrase, with and without prior treatment with Src kinase, 
as indicated, with [32P]yATP as phosphate donor. Products were immu- 
noprecipitated with control or IN-specific antibody, and analyzed by 
SDS-PAGE and autoradiography. 
(B) Same experiment, using Src-treated MA variants and a recombi- 
nant molecule corresponding to amino acids 50-212 of integrase. Im- 
munoprecipitations were performed with IN-specific antibody, and de- 
tection by Western blot with antiserums against MA and IN. 
this kinase to induce the incorporation of phosphate into 
the MAYTaZF mutant (data not shown). Wild-type and mutant 
forms of MA were mixed with recombinant HIV-1 IN, with 
or without prior phosphorylation with Sm. The formation of 
MA-IN complexes was monitored by immunoprecipitation 
with IN-specific or control antibodies, followed by gel elec- 
trophoresis and either autoradiography (if radiolabeled 
phosphate had been used in the kinase reaction) (Figure 
5A) or Western blot with IN- and MA-specific antiserums 
(Figure 58). No association of IN with MAY13*~ or with the 
nonphosphorylated form of wild-type MA was observed 
(Figure 5A, lanes 7-9). In contrast, the tyrosine phosphory- 
lation of MA promoted the formation of a complex with 
IN (Figure 5A, lane 10). Depleting Src-treated MA with a 
phosphotyrosine-specific antibody prevented the forma- 
tion of MA-IN complexes (data not shown). Therefore, the 
interaction between MA and IN is tyrosine phosphoryla- 
tion-dependent and requires neither additional viral pro- 
teins nor the viral genome. 
To explore further the requirements for the interaction 
between IN and tyrosine-phosphorylated MA, a truncated 
version of integrase corresponding to the minimal catalyti- 
cally active core domain of this enzyme, from amino acid 
50 to amino acid 212 (Bushman et al., 1993; Vink et al., 
1993) was tested for its ability to bind phosphotyrosine- 
containing MA (Figure 5B). As observed with the full-length 
molecule, INsom2,, associated with the tyrosine-phos- 
phorylated form of wild-type MA, but failed to bind to the 
MAYllPF variant (Figure 58, lanes 7 and 8). 
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That tyrosine phosphorylation of MA was required for Second, the ability of various amino acids to compete 
IN binding did not prove that the modified C-terminal resi- for this reaction was evaluated (Figure 6B). Preincubating 
due of MA was itself involved in mediating the interaction integrase with tyrosine, threonine, or phosphothreonine 
between the two proteins. Instead, it could have been that did not interfere with the association of this protein with 
this modification induced a conformational change in MA MA (compare lane 2 with lanes 3,5, and 6), nor did serine 
that resulted in exposing a distantly placed motif responsi- or phosphoserine (data not shown). In contrast, phospho- 
ble for IN recognition. To address this question, three ex- tyrosine completely blocked the interaction between the 
periments were performed. two molecules (lane 4). 
First, the resistance of tyrosine-phosphorylated MA to 
phosphatase was evaluated, before and after formation 
of a complex with integrase (Figure 6A). Calf intestinal 
phosphatase efficiently removed the phosphate from tyro- 
sine-phosphorylated MA (lane 2) and as a consequence 
prevented the formation of MA-IN complexes (lane 5). In 
contrast, when preformed MA-IN complexes were ex- 
posed to phosphatase, tyrosine-phosphorylated MA was 
resistant to dephosphorylation (lanes 3 and 6) and the 
treatment did not disrupt the association between the two 
proteins (lane 6). This indicates that the C-terminal phos- 
photyrosine of MA is protected from the action of phospha- 
tase following integrase binding. 
Finally, preincubating tyrosine-phosphorylated MA with 
an excess of anti-phosphotyrosine antibody prevented the 
formation of MA-IN complexes (data not shown). On the 
basis of these experiments, it can be concluded that a 
phosphotyrosine-binding site in the core domain of integ- 
rase is responsible for recognizing the phosphorylated 
C-terminus of MA directly. 
Discussion 
This study reveals how the karyophilic properties of MA 
are conferred to the HIV nucleoprotein complex, thereby 
governing virus nuclear import in nondividing cells. MA 
carries two motifs, a myristoylation signal and an NLS, 
that exert conflicting influences on its subcellular localiza- 
tion. In virus producer cells, the protein associates with 
the plasma membrane as part of the Gag precursor by 
virtueof its N-terminal myristate. Asubset of MA molecules 
is then phosphorylated on C-terminal tyrosineduring virion 
maturation. This modification induces the formation of a 
complex with integrase, triggering the redistribution of 
some MA to the inner regions of the particle. After fusion 
of the virus and target cell membranes, tyrosine-phos- 
phorylated MA, still associated with integrase, becomes 
part of the uncoated viral nucleoprotein complex, together 
with theviral genome, RT, NC, and Vpr. It can then exert its 
karyophilic role, most probably through the NLS-mediated 
recognition of a cytoplasmic receptor that directs the HIV 
nucleoprotein complex to the nucleopore. 
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Figure 6. The C-terminal Phosphotyrosine of MA Is Involved in Mediat- 
ing MA-IN Complex Formation 
(A) Calf intestine phosphatase was added to Src-treated MA as indi- 
cated, before (lanes 2 and 5) or after (lanes 3 and 6) performing an MA- 
IN-binding reaction. Products were separated by SDS-PAGE, either 
directly(lanes I to 3)or afterimmunoprecipitation with anti-IN antibody; 
results were analyzed by Western blot with antibodies against MA (top) 
or phosphotyrosine (bottom). 
(6) Sk-treated wild-type and tyrosine-mutated versions of recombinant 
MA were mixed with recombinant integrase preincubated with various 
competitors as indicated. Products were immunoprecipitated with IN- 
specific antibody and analyzed by Western blot with a mixture of anti- 
bodies against MA and integrase. 
Tyrosine phosphorylation enhances the incorporation 
of MA into the virus core and is required for its association 
with the uncoated viral nucleoprotein complex. Further- 
more, all MA molecules present in cores and in partially 
purified nucleoprotein complexes can be immunoprecipi- 
tated with a phosphotyrosine antibody, at least in the pres- 
ence of low concentrations of detergent. Nevertheless, in 
the presence of high concentrations of detergent, not all 
MA molecules contained in the HIV-1 nucleoprotein com- 
plex are immunoprecipitated by the anti-phosphotyrosine 
antibody (data not shown). Although dephosphorylation of 
the protein during preparation of the extracts cannot be 
formally excluded, it suggests that MA exists as a mixed 
multimer, comprising both tyrosine-phosphorylated and 
nontyrosine-phosphorylated subunits. The recently ob- 
tained crystal structure of MA supports this hypothesis, 
as it reveals that MA assembles as a close-packed oligo- 
mer (C. Hill and W. Sunquist, personal communication). 
Notably, a subpopulation of virion-associated MA is phos- 
phorylated on several serines, but not on tyrosine (S. S. 
and D. T., unpublished data). It will be interesting to deter- 
mine whether these serine-phosphorylated MA molecules 
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are the ones that are incorporated in cores and in uncoated 
nucleoprotein complexes, together with tyrosine-phos- 
phorylated MA. 
Three lines of evidence suggest that the modified C-ter- 
minus of MA is itself involved in contacting integrase. First, 
the covalent bond between phosphate and the C-terminal 
tyrosine of MA becomes resistant to the action of phospha- 
tase once MA associates with integrase. Second, preincu- 
bation of integrase with phosphotyrosine efficiently pre- 
vents MA binding, whereas tyrosine, threonine, serine, 
phosphothreonine, and phosphoserine have no such ef- 
fect. Finally, preincubation of MA with anti-phospho- 
tyrosine antibodies inhibits MA-IN complex formation. 
The central region of integrase must therefore contain a 
motif capable of recognizing phosphotyrosine, either as 
a free amino acid or as the C-terminal residue of MA. The 
immunoprecipitation of MA-IN complexes with anti- 
phosphotyrosine antibodies may seem incompatible with 
this model. However, this paradox is likely a consequence 
of MA multimerization. Of note, the phosphotyrosine- 
specific antibody did not immunoprecipitate MA-IN com- 
plexes formed in vitro (data not shown), suggesting that 
in that case MA did not oligomerize. 
Prior to MA, we had not seen a protein phosphorylated 
on a C-terminal tyrosine. It is therefore not surprising to 
find no similarity between the sequence of the IN core 
and that of previously described phosphotyrosine-binding 
domains, such as Src homology domain 2 (Pawson and 
Schlessinger, 1993), or the recently described PID (phos- 
photyrosine interaction domain) (Blaikie et al., 1994; Kava- 
naugh and Williams, 1994; Bork and Margolis, 1995). A 
critical step of the HIV life cycle thus appears to be medi- 
ated by a novel type of protein-protein interaction. 
Experimental Procedures 
DNA Constructions 
Plasmid R8, containing a full-length HIV-1 proviral DNA in which all 
reading frames are functional, was obtained by cloning a BssHII- 
BamHl fragment from HIV-lNLti (Myers et al., 1992) into the previously 
described R7 construct (Kim et al., 1989). Plasmid HIV.2ROD10, a gift 
from M. Emerman, expresses the HIV-2noo proviral DNA. PCR- 
mediated mutagenesis was used to substitute a phenylalanine for the 
C-terminal tyrosine of MA in R8 and in HIV-2ROD,0, and to introduce a 
stop codon at the 3’ end of the RT coding sequence. Recombinant 
HIV-l MA carrying an N-terminal histidine tag was produced in E. 
coli by using the bacterial expression vector PET-15b (Novagen) and 
purified by affinity chromatography on a nickel-Sepharose column 
according to the instructions of the manufacturer. Full-length and trun- 
cated versions of recombinant integrase were generated as previously 
described (Bushman et al., 1993). 
Cells 
Cell lines were grown as previously described (Aiken et al., 1994). 
HIV-l-infected Molt IIIB human T lymphoid cells (Farnet and Haseltine, 
1991)were agiftfrom C. Farnet, Salk Institute, and CDCpositive HeLa- 
derived P4-2 cells (Charneau et al., 1994) were a gift from F. Clavel, 
Pasteur Institute. 
Transfections and Infections 
Transfections and infections were performed as previously described 
(Aiken et al., 1994; Gallay et al., 1995). Viral stocks of R8 and HIV-2 
derivatives were produced either by transfection of human fibroblastic 
293 cells, or by electroporation of CEM cells. SupTl cells were infected 
either by coculture with Molt IIIB cells at a ratio of 5O:i (2 x IO’ Molt 
IIIB cells per IO9 SupTl cells) or by cell-free virus infection (80 pg of 
p24 antigen per lo9 SupTl cells). P4-2 cells were infected by the 
addition of cell-free virus (50 Kg of p24 antigen per lOa P4-2 cells). At 
various times postinfection, cells were washed three times with PBS, 
trypsinized, and washed again. 
Core and Nucleoprotein Complex Purification 
Purification of HIV-2 cores was performed according to a technique 
optimized by V. Kewalramani and M. Emerman. In brief, 800 ml of 
supernatant from CEM cells acutely infected with HIV-Pnoo was filtered 
through a 0.45 pm (pore size) nitrocellulose membrane and centrifuged 
through a 20% sucrose cushion at 23,000 rpm in an SW28 rotor for 
2 hr. Pelleted virions were resuspended in 500 ~1 of PBS containing 
1% lgepal CO-630 @hone-Poulenc) and immediately overlayed onto 
a 20%-60% sucrose gradient. After 24 hr at 20,000 rpm in an SW40 
rotor, fractions were collected and tested for their content in various 
viral proteins. For MA-IN coimmunoprecipitation studies, cores were 
further treated with 0.0025% Brij-96 (Sigma). HIV-l viral nucleoprotein 
complexes were purified from SupTl cells acutely infected with IIIB 
viruses at 5 hr postinfection as previously described, with 0.025% 
Brij-96 as detergent (Miller et al., 1995). Subcellular fractionation of 
acutely infected P4-2 cells was performed as recently described (Gal- 
lay et al., 1995). 
Detection of Viral Proteins 
HIV-I p24 antigen values in virus and cell extracts were measured 
by enzyme-linked immunosorbent assay (ELISA) (DuPont). The CA 
content of HIV-2 virions and cores was determined by using the same 
assay. This ELISA is approximately 1000-5000 times less sensitive 
for the HIV-2 CA than for its HIV-1 counterpart, so that the numbers 
shown in Figure 1 only represent relative values. RT activity was moni- 
tored by a so-called exogenous RT assay (Goff et al., 1961), with 
minor modifications (Aiken and Trono, 1995). Other viral proteins were 
detected by Western blot with specific antibodies, with or without prior 
immunoprecipitation, as previously described (Gallay et al., 1995). 
Polyclonal serums against HIV-1 MA and IN were obtained by immuniz- 
ing rabbits with E. coli-produced recombinant proteins, Both antisera 
cross-react with their respective HIV-2 counterparts, although the anti- 
HIV-1 MA antibody fails to immunoprecipitate HIV-2 MA. Rabbit anti- 
phosphotyrosine serum wasagift from B. Sefton, Salk Institute. Rabbit 
anti-HIV-l Vpr was a gift from L. Ratner, obtained through the National 
Institutes of Health AIDS Research and Reference Program. Rabbit 
anti-NC serum was a gift of L. Henderson, National Cancer Institute- 
FCRDC. Monoclonal antibodies against HIV-1 MA, HIV-1 RT, and 
HIV-2 CA were purchased from Advanced Biotechnologies, Incorpo- 
rated, and monoclonal antibodies specific for HIV-2 MA, HIV-l Env, 
and HIV-2 Env were acquired from Biotech Research Laboratories, 
Genzyme, and Intracel, respectively. 
MA-lntegrase In Vitro Binding Assays 
Recombinant histidine-tagged MA was tyrosine phosphorylated in vitro 
with recombinant mouse Src expressed in SF9 insect cells (a gift from 
M. Broome and T. Hunter, Salk Institute). Kinase reactions were con- 
ducted for 2 hr at 37OC, using 20 ng of Src for 5 trg of MA in 30 frl of 
a solution containing 50 mM Tris-HCI (pH 7.5), 10 mM MgCI,, 5 mM 
MnC&, 50 mM NaCI, 1 mM orthovanadate, and 0.1% NP40, 5 mM 
cold ATP, with or without 30 t&i of [32P]yATP. The product was purified 
by affinity chromatography on nickel-Sepharose beads, as previously 
described (Gallay et al., 1995). MA (100 ng) was then incubated with 
recombinant full-length IN (100 ng), or with its truncated version, 
lN50-212, for 1 hr at 37OC in 1 ml of binding buffer (20 mM HEPES [pH 
7.31, 150 mM KCI, 5 mM MgCI,, 1 mM dithiothreitol, 0.25% Brij-96). 
Complexeswereimmunoprecipitated byusinganti-IN antibodiescova- 
lently coupled to CNBr-activated agarose for 2 hr at 4OC. After ten 
washes with binding buffer supplemented with 0.25 M NaCI, immuno- 
precipitated proteins were eluted from the beads with SDS-loading 
buffer and loaded onto a 10% SDS-polyacrylamide gel. Proteins were 
then transferred to PVDF membrane by electroblotting and analyzed 
by Western blotting with anti-IN, anti-MA, or anti-phosphotyrosine anti- 
bodies. Calf intestinal phosphatase (2 U) was used to treat 100 ng of 
MA for 2 hr at 37°C. In competition experiments, 100 ng of IN was 
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preincubated with 1 mM of free amino acids for 1 hr at 37%, in 1 ml 
of binding buffer (pH 7.3), without detergent. 
PCR Analysis of Acutely Infected Cells 
PCR analysis was performed as previously described (Trono, 1992). 
The sequences of HIV-specific primers are as follows (positions of 
nucleotides in the HIV-lHxsz sequence, according to Myerset al. 119921, 
are indicated in parentheses). Vif 6, GGGAAAGCTAGGGGATGGTTT- 
TAT (5136 to 5159); Vif 7, CAGGGTCTACTTGTGTGCTATTC (5340 
to 5317). Vif 6 and Vif 7 amplify elongated minus-strand DNA. 
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